| Bioactivity | Linifanib (ABT-869) is a potent and orally active multi-target inhibitor of VEGFR and PDGFR family with IC50s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib shows prominent antitumor activity. Linifanib has much less activity against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. Linifanib is a specific miR-10b inhibitor that blocks miR-10b biogenesis[1][2]. | ||||||||||||
| Invitro | Linifanib (0-10000 nM; 72 hours) inhibits in vitro the cell proliferation of 8305C and 8505C cell lines in a concentration-dependent manner[3].Linifanib significantly decreased the levels of phospho-CSF-1R after 24 h and 72 h in both 8505C and 8305C cells[3]. Cell Viability Assay[3] Cell Line: | ||||||||||||
| Name | Linifanib | ||||||||||||
| CAS | 796967-16-3 | ||||||||||||
| Formula | C21H18FN5O | ||||||||||||
| Molar Mass | 375.40 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
Linifanib
CAS: 796967-16-3 F: C21H18FN5O W: 375.40
Linifanib (ABT-869) is a potent and orally active multi-target inhibitor of VEGFR and PDGFR family with IC50s of 4, 3, 6
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.